Baird analyst David Koning downgrades Verra Mobility (NASDAQ:VRRM) from Outperform to Neutral.
JP Morgan Maintains Neutral on Immunogen, Raises Price Target to $9
JP Morgan analyst Daniel Wolle maintains Immunogen (NASDAQ:IMGN) with a Neutral and raises the price target from $8 to $9.